Category

Smartkarma Newswire

Analyzing Jiangsu Hengli Highpressure Oil Cylinder (601100) Earnings: 1Q Net Income Reveals Promising Buy Indications

By | Earnings Alerts
  • Jiangsu Hengli reported a net income of 601.9 million yuan for the first quarter.
  • The company’s revenue for the same period was 2.36 billion yuan.
  • The market has a positive outlook for the company with 27 buy ratings.
  • There are mixed sentiments as well with 6 hold ratings.
  • Only 1 analyst has issued a sell rating.

A look at Jiangsu Hengli Highpressure Oil Cylinder Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth4
Resilience5
Momentum4
OVERALL SMART SCORE3.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

In analyzing the long-term outlook for Jiangsu Hengli Highpressure Oil Cylinder, a comprehensive evaluation utilizing Smartkarma Smart Scores reveals a promising future. With commendable scores in Growth and Resilience, the company showcases a strong potential for expansion and a solid ability to withstand market fluctuations. Additionally, the Momentum score indicates positive momentum in the company’s performance, further bolstering its outlook. While the Value score could see improvement, the overall outlook remains optimistic based on the favorable ratings across various factors.

Jiangsu Hengli Hydraulic Co Ltd, specializing in the development, manufacturing, and sale of high-pressure oil cylinders and hydraulic systems, is positioned for long-term success. The company’s product portfolio, including fuel tanks and non-standard cylinders for heavy equipment, underscores its niche expertise in serving industrial needs. With competitive scores in Dividend, Growth, Resilience, and Momentum, Jiangsu Hengli Highpressure Oil Cylinder demonstrates a robust foundation for sustained growth and resilience in the market.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Decline in Earnings: Chongqing Zhifei Biological Products (300122) Posts 1Q Net Income of 1.46B Yuan, Down by 28% YoY

By | Earnings Alerts
  • Zhifei Biological’s net income for the first quarter is 1.46 billion yuan.
  • There has been a decrease in net income by 28% year on year.
  • The reported revenue for the same quarter is 11.4 billion yuan.
  • The revenue indicates a rise of 1.8% year on year.
  • The noted revenue has surpassed the estimate of 11.23 billion yuan.
  • A total of 26 buys, 1 hold, and 0 sells have been recorded for the company’s stocks.
  • The comparisons to past results are based on values reported by the company’s original disclosures.

A look at Chongqing Zhifei Biological Products Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth5
Resilience3
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Chongqing Zhifei Biological Products Company Ltd is looking towards a promising long-term future as indicated by its Smartkarma Smart Scores. With a solid Growth score of 5, the company demonstrates strong potential for expansion and development in the market. Additionally, the company has achieved respectable scores in Resilience and Momentum, showing that it is well-positioned to withstand challenges and maintain a stable upward trajectory.

While Chongqing Zhifei Biological Products may have room to improve in terms of Value and Dividend scores, its overall outlook appears positive with a focus on growth and resilience. The company’s dedication to researching, manufacturing, and selling vaccines and biological products positions it as a key player in the industry, making it one to watch for investors seeking opportunities in the healthcare sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Chongqing Zhifei Biological Products (300122) Earnings: FY Net Income Falls Short of Estimates

By | Earnings Alerts
  • Net Income: Zhifei Biological reported a fiscal year net income of 8.07 billion yuan.
  • Income vs Estimates: This figure fell short of the estimated 8.99 billion yuan.
  • Revenue: The company’s revenue stood at 52.92 billion yuan.
  • Revenue vs Estimates: It was more than the estimated revenue of 49.44 billion yuan.
  • Investor Ratings: Zhifei Biological received 26 buy ratings, a single hold rating, and no sell ratings.

A look at Chongqing Zhifei Biological Products Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth5
Resilience3
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Analysts have highlighted a positive long-term outlook for Chongqing Zhifei Biological Products Company Ltd. based on its Smartkarma Smart Scores. With a high growth score of 5, the company is expected to experience strong expansion in the coming years. This is supported by its solid momentum score of 3, indicating that it is well-positioned for continued growth in the market. Additionally, the company has a respectable dividend score of 3, suggesting it may provide steady returns to investors over time.

Despite the average value score of 2, the company’s resilience score of 3 indicates its ability to weather challenging market conditions. Overall, Chongqing Zhifei Biological Products is recognized for its research, manufacture, and sale of vaccines and biological products, aligning with its commitment to delivering prevention products, blood products, diagnostic reagents, and therapeutic agents to the market.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

IFlytek Co Ltd A (002230) Earnings: Significant Quarterly Loss Amidst Revenue Growth and Business Expansion

By | Earnings Alerts
  • Iflytek’s net loss for Q1 2024 stands at 300.5 million yuan, drastically increased from the previous year’s loss of 57.9 million yuan.
  • Revenue saw a rise by 26% year on year to reach 3.65 billion yuan.
  • The loss per share rose sharply from 2.0 RMB cents to 13 RMB cents year on year.
  • The net income fell sharply by 419% in comparison to the 2023 year results.
  • Total revenue for 2023 was 19.65 billion yuan, marking a 4.4% increase year on year but fell short of the estimated 20.42 billion yuan.
  • Revenue from Medical Business stood at 539.5 million yuan, falling short of the estimated 634.9 million yuan.
  • Open Platform Revenue went beyond expectations to reach 3.94 billion yuan against the estimated 3.38 billion yuan.
  • Car Intelligent Networking Related Services Revenue exceeded estimates and totaled 695.5 million yuan.
  • Smart Financial Products & Solutions Revenue was slightly higher than expected at 288.8 million yuan.
  • Operator Related Business Revenue was 2.10 billion yuan, which was less than the estimated 2.23 billion yuan.
  • R&D expenses stood at 3.48 billion yuan, less than the estimated 3.71 billion yuan.
  • Iflytek has been rated 31 times as a buy, 5 times as a hold, and 0 times as a sell.

A look at IFlytek Co Ltd A Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth3
Resilience3
Momentum5
OVERALL SMART SCORE3.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, the long-term outlook for IFlytek Co Ltd A appears promising. The company excels in momentum, scoring the highest possible rating, indicating strong positive price momentum. This suggests that IFlytek Co Ltd A is experiencing upward trending stock prices, which can be a positive indicator for future performance.

Furthermore, IFlytek Co Ltd A demonstrates strength in growth and resilience, with scores of 3 for both factors. This implies that the company has potential for future expansion and is equipped to withstand challenges. While the value and dividend scores are moderate at 2, the overall outlook for IFlytek Co Ltd A seems positive, positioning the company well for potential growth in the long term.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Shenzhen Transsion Holdings (688036) Earnings Surpass Estimates: FY R&D Expenses and Dividend Highlights

By | Earnings Alerts
  • Shenzhen Transsion’s Fiscal Year Research & Development (R&D) expenses came in at 2.26 billion yuan, which is lower than the predicted estimate of 2.51 billion yuan.

  • The company announced a final dividend per share of 3 yuan.

  • The stock currently holds a favorable rating with 22 buy recommendations, 1 hold recommendation, and no sells.


A look at Shenzhen Transsion Holdings Smart Scores

FactorScoreMagnitude
Value2
Dividend4
Growth4
Resilience5
Momentum5
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Shenzhen Transsion Holdings, a mobile phone producer, has a promising long-term outlook according to Smartkarma’s Smart Scores. With strong ratings in Growth, Resilience, and Momentum, the company appears well-positioned for future success. Its high scores in Dividend and Resilience indicate a stable financial position and potential for consistent returns to investors.

Shenzhen Transsion Holdings, known for its global presence in mobile phone markets, continues to show strength in key areas that drive investor confidence. The company’s focus on growth, coupled with solid momentum and resilience, suggests a positive trajectory for its future performance. Investors may find Shenzhen Transsion Holdings an attractive opportunity based on its strong Smart Scores across various factors.

Summary of the company: Shenzhen Transsion Holdings Co., Ltd. is a leader in the production and sale of mobile phones, offering a range of services from research and development to after-sales support. The company’s products are marketed worldwide, showcasing its global reach and influence in the mobile phone industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Albertsons Cos (ACI) Showcases Surprising 4Q Earnings, Beats EPS Estimates Despite Ebitda Decline

By | Earnings Alerts
  • Albertsons Cos. 4Q reports an adjusted EPS of 54c, which is an improvement compared to the estimate of 51c but it’s lower than last year’s 79c.
  • Its identical sales have grown by 1%, which sits a bit lower than the estimate of 1.17% and is notably lower than last year’s growth of 5.6%.
  • The company’s 4Q adjusted EBITDA is at $916 million, which has decreased by 13% y/y and is slightly lower than the estimate of $917 million.
  • The gross profit margin stands at 28%, an increase compared to last year’s 27.8% and above the estimate of 27.6%.
  • Net sales and other revenue for 4Q measured at $18.3 billion, matching the y/y figure but falling slightly short of the estimate which was $18.46 billion.
  • Considering this performance, analysts’ recommendations currently stand at 6 buys, 12 holds, and 0 sells.

A look at Albertsons Cos Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Albertsons Companies, Inc., a retail company in the United States, is met with a mixed bag of Smart Scores indicating its long-term prospects. While showcasing moderate performance in Dividend, Growth, and Momentum factors, the company falls short in Value and Resilience, receiving lower scores in these areas. Despite facing challenges in terms of value and resilience, Albertsons remains steady in dividend payments, shows promising growth potential, and maintains a decent momentum in the market.

On the whole, Albertsons Cos appears to have room for improvement in certain aspects of its operations to enhance its overall outlook. With a keen focus on strengthening its value and resilience factors, the company can strive for a more balanced and favorable long-term performance in the competitive retail sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Sungrow Power Supply (300274) Earnings: FY Net Income Misses Estimates Despite Revenue Surge in Power Conversion Equipment and New Energy Investment

By | Earnings Alerts
  • Sungrow Power Supply‘s net income for FY was 9.44 billion yuan, showing a substantial increase from last year’s 3.59 billion yuan, albeit slightly missing estimates of 9.55 billion yuan.
  • The company’s revenue was 72.3 billion yuan, a significant 79% growth from the previous year, surpassing estimates of 71.23 billion yuan.
  • Revenue from Power Conversion Equipment, such as Photovoltaic inverters, increased by 61% to reach 27.65 billion yuan, beating the estimate of 26.93 billion yuan.
  • Revenue from New Energy Investment and Development reached 24.73 billion yuan, up from last year’s 11.6 billion yuan and easily surpassing estimates of 19.03 billion yuan.
  • Energy Storage System revenue was 17.80 billion yuan, showing a growth of 76% y/y, although it was below estimates of 20.84 billion yuan.
  • Photovoltaic Power Generation Revenue took a dip of 9.3% to 567.2 million yuan, falling short of the estimate of 864.7 million yuan.
  • Other businesses contributed a revenue of 1.49 billion yuan, more than doubling that of the last year’s 722.8 million yuan, albeit missing estimates of 1.69 billion yuan.
  • The final dividend per share was reported to be 96.5 RMB cents.
  • With respect to first-quarter results, the net income reached 2.10 billion yuan, marking an increase of 39% y/y, while revenue was essentially stable at 12.61 billion yuan (increase of just 0.1% y/y).
  • Sungrow Power Supply’s performance earned them 32 buys, 1 hold, and 1 sell.

A look at Sungrow Power Supply Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth5
Resilience3
Momentum5
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Sungrow Power Supply is positioned for strong long-term growth with high scores in Growth and Momentum. The company develops, sells, and services solar PV inverters and other power supply products, catering to the renewable energy sector. With a Growth score of 5, Sungrow Power Supply is expected to expand its market presence and achieve significant revenue growth in the coming years. Additionally, a Momentum score of 5 indicates positive market sentiment and investor confidence in the company’s future prospects.

Although the company scores moderately on Value and Dividend factors, with scores of 2 each, Sungrow Power Supply‘s Resilience score of 3 suggests a certain level of stability and ability to navigate market challenges. Overall, Sungrow Power Supply‘s strong emphasis on growth and momentum, combined with its focus on renewable energy solutions, positions it well for future success in the ever-evolving energy industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Jinko Solar (688223) Earnings Miss Estimated Net Income, Despite Revenue Surpassing Expectations

By | Earnings Alerts
  • Jinko Solar’s net income for the financial year was 7.44 billion yuan, which unfortunately fell short of the projected estimate of 7.86 billion yuan.
  • The company’s revenue surpassed expectations, coming in at 118.68 billion yuan, with the initial estimate being 111.28 billion yuan.
  • The overall market sentiment towards the company was largely positive, with 24 buy recommendations, only 1 hold recommendation and 2 sell recommendations.

A look at Jinko Solar Smart Scores

FactorScoreMagnitude
Value3
Dividend3
Growth5
Resilience2
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Jinko Solar’s long-term outlook seems promising. With a high Growth score of 5, the company is positioned for potential expansion and development in the solar energy sector. Additionally, scoring a solid 3 in both Value and Momentum, Jinko Solar demonstrates a balanced mix of perceived worth and market traction.

However, the company’s lower Resilience score of 2 may indicate some vulnerability to economic fluctuations or industry challenges. This suggests that while Jinko Solar shows strong potential for growth, it may need to focus on enhancing its resilience to external factors. Overall, Jinko Solar’s Smart Scores paint a picture of a company with strong growth prospects and market appeal, albeit with some room for improvement in terms of resilience.

### Jinko Solar Co., Ltd. manufactures photovoltaic products. The Company develops, manufactures, and markets crystalline ingots, wafers, mono-crystalline photovoltaic panels, and multi-crystalline photovoltaic panels. Jinko Solar markets its products worldwide. ###


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Wingtech Technology (600745) Earnings Miss Experts’ Projections: A Look into 1Q Net Income Results

By | Earnings Alerts
  • Wingtech Tech’s net income for the first quarter fell short of estimates, coming in at 143.4 million yuan compared to the estimated 701.8 million yuan.
  • However, the company’s revenue surpassed expectations, reaching 16.25 billion yuan against the estimated 15.85 billion yuan.
  • Earnings per share (EPS) were reported at 12 RMB cents. This fall below the expectation of 54 RMB cents per share.
  • Despite these results, Wingtech Tech has remained a favoured investment, with 24 buys and 2 holds. Interestingly, there were no sells.

A look at Wingtech Technology Smart Scores

FactorScoreMagnitude
Value4
Dividend1
Growth3
Resilience3
Momentum3
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Wingtech Technology is showing promise in the long run with a solid Value score of 4, indicating a positive outlook for its financial health and performance. However, investors should take note of the lower Dividend score of 1, suggesting limited returns in terms of dividend payouts. The company’s Growth score of 3 reflects moderate potential for expansion, coupled with Resilience and Momentum scores both at 3, indicating a stable and steady performance trajectory.

Specializing in manufacturing communications equipment such as mobile phones and tablets, Wingtech Technology also diversifies its portfolio with involvement in real estate development, hotel management, and financing. With a mixed bag of Smart Scores, prospective investors may consider the company’s overall outlook as cautiously optimistic, balancing growth potential with dividend expectations.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Recordati SpA (REC) Earnings: 1Q Revenue Surpasses Estimates with a Strong Start in 2024

By | Earnings Alerts
  • Recordati’s 1Q revenue for 2024 has beaten estimates by reaching €607.8 million, significantly higher than the estimated €584.3 million.
  • The complete financial results for this quarter will be made public on May 9, 2024.
  • Compared to Q1 of 2023, the revenue for the same time period in 2024 has increased by 10.2% or even 10.9% if the revenue generated from Avodart®/Combodart® (€27.5m) is excluded.
  • This excellent performance at the beginning of the year was experienced by both business entities and the international and Türkiye phasing patterns were similar to those of Q1 2023.
  • Despite the negative impact of currency exchange of €31.2m (mostly on Türkish Lira, offset by price inflation) was felt during Q1, the company managed to overcome this setback.
  • Regarding the share rating, 4 are recommending to buy, 7 vouch for hold and 1 suggests sellingRecordati shares.

A look at Recordati SpA Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth3
Resilience3
Momentum4
OVERALL SMART SCORE3.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Recordati SpA, a pharmaceutical company, holds promising long-term prospects according to Smartkarma Smart Scores analysis. With a solid score in Value and respectable ratings in Dividend, Growth, Resilience, and Momentum, the company appears to be positioned well in various key areas. This suggests a positive outlook for Recordati SpA in the long run, supported by its strong performance across multiple critical factors.

Recordati SpA, known for manufacturing pharmaceuticals worldwide, has received encouraging Smart Scores across key indicators. The company’s competitive positioning in terms of Dividend, Growth, Resilience, and Momentum, complemented by a fair Value score, underlines its potential for sustained growth and stability. Investors may find Recordati SpA a compelling investment option based on its overall positive assessment across these key factors.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars